http://orcid.org/0000-0001-9754-1011
References
- Crane DR. 2019. Report of Evaluation of Cosmetics and Cosmetic Talc for FDA.
- Hillerdal G. 1999. Mesothelioma: cases associated with non-occupational and low dose exposures. Occup Environ Med. 56(8):505–513.
- Mark EJ, Yokoi T. 1991. Absence of evidence for a significant background incidence of diffuse malignant mesothelioma apart from asbestos exposure. Ann NY Acad Sci. 643(1 The Third Wav):196–204.
- Marsh GM, IIerardi AM, Benson SM, Finley BL. 2019. Occupational exposures to cosmetic talc and risk of mesothelioma: an updated pooled cohort and statistical power analysis with consideration of latency period. Inhal Toxicol. 31(6):213–223.
- McDonald JC. 1985. Health implications of environmental exposure to asbestos. Environ Health Perspect. 62:319–328.
- Newman S. 2001. Biostatistical methods in epidemiology. New York (NY): Wiley.
- Steffen JE, Tran T, Fassler EA, Egilman DS. 2017. Presence of Asbestos in Consumer Talc Products: Evaluating a “Zero Tolerance” Policy. APHA Annual Meeting; Nov 7; https://apha.confex.com/apha/2017/meetingapp.cgi/Paper/391840 and https://www.researchgate.net/publication/321542650_Presence_of_asbestos_in_consumer_talc_products_Evaluating_a_zero_tolerance_policy
- Strauchen J. 2011. Rarity of malignant mesothelioma prior to the widespread commercial introduction of asbestos: the Mount Sinai Autopsy Experience 1883–1910. Am J Ind Med. 54(6):467–469.
- Stuart J. 1974. Asbestos and other contaminants in talc. FDA Cosmetics Division Memo, Project Number 00679.
- Teta MJ, Mink PJ, Lau E, Sceurman BK, Foster ED. 2008. US mesothelioma patterns 1973–2002: indicators of change and insights into background rates. Eur J Cancer Prev. 17(6):525–534.